Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)


beclometasone / formoterol / glycopyrronium bromide

This medicine is authorised for use in the European Union.


An overview of Riarify and why it is authorised in the EU

Riarify is a medicine used in adults to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Riarify is used for maintenance (regular) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two other COPD medicines, a beta-2 agonist and an inhaled corticosteroid.

This medicine is the same as Trimbow, which is already authorised in the EU. The company that makes Trimbow has agreed that its scientific data can be used for Riarify (‘informed consent’).

Riarify contains the active substances beclometasone, formoterol and glycopyrronium bromide.

This EPAR was last updated on 26/04/2018

Authorisation details

Product details
Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)
Agency product number
Active substance
  • beclometasone dipropionate anhydrous
  • formoterol fumarate dihydrate
  • glycopyrronium
International non-proprietary name (INN) or common name
beclometasone / formoterol / glycopyrronium bromide
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Chiesi Farmaceutici S.p.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Via Palermo 26/A
43122 Parma

Product information

23/04/2018 Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) - EMEA/H/C/004836 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Assessment history

How useful was this page?

Add your rating
1 rating